Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Kirsten Rat Sarcoma Viral Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis, 2022
Kirsten Rat Sarcoma Viral Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis, 2022
Kirsten Rat Sarcoma Viral (KRAS) oncogene is the mutated isoform of RAS, having the most common mutations in cancer, accounting for 85% of RAS-driven human cancers. KRAS basically acts as an on/off switch for cell growth with a normal function of regulating cell growth, but when mutated, results in uncontrollable cell growth. KRAS inhibitors bind to the cysteine residue in KRAS G12C mutations and lock the protein in its inactive form, thereby arresting cell proliferation and suppressing tumor growth. The KRAS inhibitors can be used for the treatment of non-small cell lung cancer, pancreatic cancer, colorectal cancer, and endometrial cancer. In the USA and Europe, the mutation of KRAS (G12C) mutation is estimated to affect more than 70,000 patients with occurrence in 14% of non-small cell lung cancer patients (approximately 44,000 patients), in 3-4% of colorectal cancer patients (approximately 20,000 patients), and in 2% of pancreatic cancer patients (approximately 4,000 patients.) Similarly, for KRAS (G12D), it is estimated to affect 1,80,000 patients in the USA and Europe with occurrence in 36% of pancreatic patients, 12% of colorectal cancer patients, 6% of endometrial cancer patients, 4% of NSCLC adenocarcinoma patients. Amgen, Mirati Therapeutics, Taiho Oncology, and Bayer are currently providing KRAS inhibitors for the treatment of cancer patients in the market. Apart from these molecules, KRAS-Ioder, developed by Silenseed is currently in phase-II clinical trial.
Approved Drug Molecules for KRAS Inhibitors
LUMAKRAS (Sotorasib)
KRAZATI (Adagrasib)
LONSURF (Trifluridine and Tipiracil)
STIVARGA (Regorafenib)
Drugs under the Pipeline for KRAS Inhibitors
KRAS-Ioder (siG12D-LODER) - Phase-II
Library TCR - T-cell therapy - Phase-II
anti-KRAS G12D mTCR PBL - Phase-I/II
JAB-3312 - Phase-I/II
ELI-002 - Phase-I/II
KRAS peptide vaccine - Phase-I
SLATE-KRAS - Phase-I/II
MSC -derived Exosomes with KrasG12D siRNA - Phase-I
GEC-225 - Phase-I
HS-10370 - Phase-I/II
Mdc3/8-KRAS vaccine - Phase-I
Clinical Activity and Development of KRAS Inhibitors
Currently, KRAS inhibitor is being developed by 22 companies, with 20 products in the pipeline, while most of them are in the initial phase of clinical trial. KRAS-Ioder is the only molecule in the Phse-II clinical trial.
Key Developments
The molecules of KRAS (G12C) inhibitors such as Lumakras (Sotorasib) and Krazati (Adagrasib) developed by Amgen and Mirati Therapeutics respectively, have obtained encouraging results in clinical trials and are currently on the market for treatment of non-small cell lung cancer. As KRAS mutation has also significant impact on the pancreatic cancer patients and colorectal cancer patients, with increase in incidence rates for both of the diseases these are expected to act as opportunities and also be the growth drivers for the KRAS inhibitor market.
Total sales at the year end of 2022 of Lumakras, by Amgen, were US$ 285 million, while in the USA alone the sales were US$ 222 million. Stivarga, which was marketed by Bayer, has seen a growth of 23.9% in sales of US$ 168 million in Q4 of 2022 to Q4 of 2021, which was US$ 129 million. Moreover, a strong volume growth and stable prices was registered for Stivarga in China in Q4 of 2022. Krazati, another approved drug for KRAS inhibitor, by Mirati Therapeutics, will have its patent expire by 2037. According to the 2020 report of World Cancer Research Fund International, Japan has the highest incidence rate for colorectal cancer (1,48,505 patients), followed by Spain (24,610 patients-men), and UK (23,234 patients-women). Japan also tops the incidence rate for pancreatic cancer (44,307 patients), followed by Germany (21,541 patients) proving the market potential for KRAS inhibitors.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Lumakras (Sotorasib), Krazati (Adagrasib), Lonsurf (Trifluridine and Tipiracil) and, Stivarga (Regorafenib) are the approved molecules in the KRAS inhibitors.
The global sales of Lumakaras for 2022 were US$ 285 million.
Amgen, Mirati Pharmaceuticals, Taiho Oncology, and Bayer are a few major players in the KRAS inhibitors space.
More than 2,00,000 cancer patients are affected by KRAS mutation in the USA and Europe.
Pancreatic cancer, colorectal cancer, endometrial cancer are some of the indications companies could focus on for the expansion of the KRAS inhibitors market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.